US OptionsDetailed Quotes
RGNX250117C30000
- 0.50
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open0.50Pre Close0 Volume4 Open Interest30.00Strike Price0.00Turnover0.00%IV287.06%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-6DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma15.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Regenxbio Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
88
27
3
$Regenxbio (RGNX.US)$
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Tuesday, 14th January at 5:00 am
• REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing
• Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis ...
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Tuesday, 14th January at 5:00 am
• REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing
• Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis ...
$iBio Inc (IBIO.US)$ $AtlasClear (ATCH.US)$ $D-Wave Quantum (QBTS.US)$ $Vaxart (VXRT.US)$ $Regenxbio (RGNX.US)$ $Nauticus Robotics (KITT.US)$ $In8bio (INAB.US)$ $AEye (LIDR.US)$ $Hyperscale Data (GPUS.US)$ $Abpro Holdings (ABP.US)$ $Yoshiharu Global (YOSH.US)$ $Color Star Technology (ADD.US)$ $P3 Health Partners (PIII.US)$ $Staffing 360 Solutions (STAF.US)$ $Nature's Miracle (NMHI.US)$
📊⚡️📊
📊⚡️📊
3
1
$Regenxbio (RGNX.US)$ SELL SELL SELL NOW EASY MONEY AND ENJOIN YOURS TAKE BREAK TOMORROW 💰💰💰😋😋😋🤩🤩🤩
Investors' pessimism about the company's revenue prospects may be causing the low P/S ratio. The company's forecast growth is lower than the wider industry, which could be contributing to the depressed P/S. It's hard to see the share price rising strongly in the near future given these circumstances.
$Regenxbio (RGNX.US)$ on 07 Feb will provide an interim clinical study update of RHX121 for treatment of neuropathic mucopolysaccharaidosis.
No comment yet
HUANG AI : thanks for sharing
magickbeans710 : Thanks man
103567231 : Bro. I saw your post, noticed those colorful ones, but they have already started to skyrocket. I dare not buy. How did you get this information? We are all too late to Buy. Thank you.
Jaguar8 OP 103567231 : Whoever is telling you to buy anyway? It’s your decision and it’s MY WATCHLIST.
Jaguar8 OP 103567231 : Unfollow me and make your own watchlist.
View more comments...